Abcam plc (ABCM) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, イギリス. 現CEOは Alan Thomas Hirzel BS,.
ABCM を有する IPO日 2020-10-22, 1,760 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.52B.
Abcam plc is a life science company headquartered in Cambridge, United Kingdom, specializing in the identification, development, and distribution of reagents and tools for scientific research, diagnostics, and drug discovery. The company's product portfolio includes primary and secondary antibodies, conjugated antibodies, immunoassays, proteins and peptides, edited cell lines, and complementary research tools such as cellular activity kits and cell signaling pathway tools. Abcam serves a diverse customer base encompassing academic institutions, research institutes, and commercial entities in the pharmaceutical, biotechnology, and diagnostics sectors. With established operations across the Americas, Europe, Asia Pacific, and other regions, the company distributes its products primarily through online channels. Founded in 1998, Abcam has established itself as a key supplier of essential scientific research materials globally.
